CN101133057B - 三唑并酞嗪化合物 - Google Patents

三唑并酞嗪化合物 Download PDF

Info

Publication number
CN101133057B
CN101133057B CN200580038057XA CN200580038057A CN101133057B CN 101133057 B CN101133057 B CN 101133057B CN 200580038057X A CN200580038057X A CN 200580038057XA CN 200580038057 A CN200580038057 A CN 200580038057A CN 101133057 B CN101133057 B CN 101133057B
Authority
CN
China
Prior art keywords
phenyl
methoxy
alkyl
alkoxy
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580038057XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101133057A (zh
Inventor
B·施米德特
S·韦恩布伦纳
D·弗洛克兹
R·库尔泽
H·特诺
H·-P·克利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of CN101133057A publication Critical patent/CN101133057A/zh
Application granted granted Critical
Publication of CN101133057B publication Critical patent/CN101133057B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN200580038057XA 2004-09-02 2005-08-31 三唑并酞嗪化合物 Expired - Fee Related CN101133057B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04104221.9 2004-09-02
EP04104221 2004-09-02
PCT/EP2005/054266 WO2006024640A2 (en) 2004-09-02 2005-08-31 Triazolophthalazines

Publications (2)

Publication Number Publication Date
CN101133057A CN101133057A (zh) 2008-02-27
CN101133057B true CN101133057B (zh) 2011-03-09

Family

ID=34929521

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580038057XA Expired - Fee Related CN101133057B (zh) 2004-09-02 2005-08-31 三唑并酞嗪化合物

Country Status (17)

Country Link
US (2) US7851472B2 (https=)
EP (1) EP1791543B1 (https=)
JP (1) JP5140427B2 (https=)
KR (1) KR101368093B1 (https=)
CN (1) CN101133057B (https=)
AT (1) ATE471324T1 (https=)
AU (1) AU2005279221C9 (https=)
BR (1) BRPI0514586A (https=)
CA (1) CA2578368C (https=)
DE (1) DE602005021894D1 (https=)
EA (1) EA014324B1 (https=)
ES (1) ES2347337T3 (https=)
IL (1) IL181271A (https=)
NO (1) NO20071127L (https=)
NZ (1) NZ553160A (https=)
WO (1) WO2006024640A2 (https=)
ZA (1) ZA200701137B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874775B1 (en) 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors
BRPI0606379A2 (pt) * 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
DK3134413T3 (da) 2014-04-23 2019-10-14 Dart Neuroscience Cayman Ltd Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
US10300064B2 (en) 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
WO2016179059A1 (en) 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
AU2018371216B2 (en) * 2017-11-23 2024-09-19 Oslo University Hospital Hf Treatment of tachycardia

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0085840A1 (en) * 1982-01-18 1983-08-17 Gruppo Lepetit S.P.A. New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives
WO1998004559A2 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
WO1999037645A1 (en) * 1998-01-21 1999-07-29 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
US6313125B1 (en) * 1997-07-29 2001-11-06 Merck Sharp & Dohme Ltd. Therapeutically active 1,2,4-triazolo[4.,3-B] pyridazine derivatives as ligands for GABA receptors
WO2002042305A1 (en) * 2000-11-23 2002-05-30 Merck Sharp & Dohme Limited Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition
WO2002081474A1 (en) * 2001-04-04 2002-10-17 Merck Sharp & Dohme Limited Triazolophthalazine / quinoline / isoquinoline derivatives which are ligands for gaba-a receptors containing the alpha 5 subtype
US6525055B1 (en) * 1998-10-29 2003-02-25 Zambon Group S.P.A. Tricyclic phthalazine derivatives as phosphodiesterase 4 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
RU2156252C2 (ru) * 1994-09-16 2000-09-20 Такеда Кемикал Индастриз, Лтд. Триазолопиридазины, способ их получения, фармацевтические композиции на их основе и способ лечения
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
EP0986562B1 (en) 1997-05-08 2002-08-07 MERCK SHARP & DOHME LTD. Substituted 1,2,4-triazolo 3,4-a]phthalazine derivatives as gaba alpha 5 ligands
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
WO2002083140A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
BRPI0606379A2 (pt) * 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
EP1874775B1 (en) * 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0085840A1 (en) * 1982-01-18 1983-08-17 Gruppo Lepetit S.P.A. New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives
WO1998004559A2 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
US6313125B1 (en) * 1997-07-29 2001-11-06 Merck Sharp & Dohme Ltd. Therapeutically active 1,2,4-triazolo[4.,3-B] pyridazine derivatives as ligands for GABA receptors
WO1999037645A1 (en) * 1998-01-21 1999-07-29 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
US6525055B1 (en) * 1998-10-29 2003-02-25 Zambon Group S.P.A. Tricyclic phthalazine derivatives as phosphodiesterase 4 inhibitors
WO2002042305A1 (en) * 2000-11-23 2002-05-30 Merck Sharp & Dohme Limited Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition
WO2002081474A1 (en) * 2001-04-04 2002-10-17 Merck Sharp & Dohme Limited Triazolophthalazine / quinoline / isoquinoline derivatives which are ligands for gaba-a receptors containing the alpha 5 subtype

Also Published As

Publication number Publication date
BRPI0514586A (pt) 2008-06-17
EA200700537A1 (ru) 2007-10-26
NO20071127L (no) 2007-02-28
ZA200701137B (en) 2008-11-26
HK1115590A1 (en) 2008-12-05
AU2005279221B2 (en) 2011-10-13
CN101133057A (zh) 2008-02-27
IL181271A (en) 2013-11-28
IL181271A0 (en) 2007-07-04
EP1791543B1 (en) 2010-06-16
US7851472B2 (en) 2010-12-14
EA014324B1 (ru) 2010-10-29
KR101368093B1 (ko) 2014-03-14
DE602005021894D1 (de) 2010-07-29
WO2006024640A2 (en) 2006-03-09
AU2005279221A1 (en) 2006-03-09
NZ553160A (en) 2010-08-27
US20090005372A1 (en) 2009-01-01
KR20070047834A (ko) 2007-05-07
ATE471324T1 (de) 2010-07-15
AU2005279221C1 (en) 2012-05-24
EP1791543A2 (en) 2007-06-06
CA2578368A1 (en) 2006-03-09
JP5140427B2 (ja) 2013-02-06
WO2006024640A3 (en) 2007-06-07
AU2005279221C9 (en) 2012-08-23
ES2347337T3 (es) 2010-10-28
JP2008511586A (ja) 2008-04-17
CA2578368C (en) 2013-07-02
US20100286140A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
CN101133057B (zh) 三唑并酞嗪化合物
CN101103033B (zh) 作为pde2抑制剂的三唑并酞嗪
US20110136803A1 (en) Triazolophthalazines
HK1115590B (en) Triazolophthalazines
HK1116776B (en) Triazolophthalazines as pde2-inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1115590

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NYCOMED INC.

Free format text: FORMER NAME: NYCOMED GMBH

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: Nycomed GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1115590

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED INC.

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: Nycomed GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110309

Termination date: 20150831

EXPY Termination of patent right or utility model